Latest close
$232.65
As of Oct 16, 2026
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Hillman Capital Management | 3.75% | 23,993 | TRIMMED (-18.8%) |
| Patient Capital Management | 2.01% | 283,697 | TRIMMED (-25.3%) |
| Perceptive Advisors | 0.90% | 276,173 | NEW |
| Causeway Capital Management | 0.65% | 278,283 | TRIMMED (-0.9%) |
| OrbiMed Advisors | 0.25% | 61,600 | HELD |
Source: SEC Form 13F filings for the quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. 13F filings cover long positions only and arrive up to 45 days after quarter-end. Fund counts here aggregate every share class mapped to this ticker; research headlines cite filer counts as they stood at publication, so a count here can differ from a headline by a holder (see Methodology, "How holder counts are counted").
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
| Institutions holding | 1,045 of 8,857 filers |
| Long-only filers among them | 1,035 |
| Change vs 2026 Q1 | +57 net · 942 entered · 885 exited |
| Shares reported, all filers | 140,647,629 |
| Reported value, all filers | $30.6B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) (SIC 2836) |
| Revenue · FY2025 | $9.9B |
| Net income · FY2025 | $1.3B |
| Total assets · FY2025 | $29.4B |
| Shares outstanding | 146,800,000 |
| Market cap (at latest close) | $34.2B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 7, 2026. Shares outstanding as reported Dec 31, 2025.
| Shares short · Sep 15, 2026 | 5,817,797 |
| Share of shares outstanding | 3.96% |
| Days to cover | 7.59 |
Shares short at recent settlements — Jun 30, 2026: 5.7M · Jul 15, 2026: 6.0M · Jul 31, 2026: 5.5M · Aug 14, 2026: 5.2M · Aug 31, 2026: 5.7M · Sep 15, 2026: 5.8M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Dec 31, 2025.
| Shares failed to deliver · Sep 15, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Sep 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jun 30, 2026: 3K · Jul 15, 2026: 0 · Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Dec 31, 2025.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 2 sales by 1 insider ($239.7K).
Source: SEC Form 4 filings, as of Oct 18, 2026. Open-market transactions only.
2 members of Congress reported buying (4 purchases vs 2 sales). Bought by Democrats and Republicans. Latest buy: Jun 5, 2026.
Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Oct 3, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.
Politicians
· Bought by Members — Last 6 months: bought by a member of the U.S. Congress
· Bought by Both Parties — Last 6 months: bought by both Democratic and Republican members
Financial Screens
· Graham — Sound finances and a long run of profits
· Cash Flow (FCF) — Positive free cash flow in each of the last 3 years, with an FCF yield of at least 5%
· Gross Profitability (Novy-Marx) — High gross profit relative to total assets
· Earnings Quality (Cash Conversion) — Profits that actually come back as cash
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· 52-Week High — Recently printed a new 52-week high
· Top Relative Strength — Top 20% of the universe by 6-month return
Key figures
· Graham — Current ratio: 2.68 · Straight profitable years: 19 · Debt ratio: 0.61 · Latest net income: $1.3B
· Cash Flow (FCF) — Latest FCF: $2.1B · FCF yield: 6.3% · Positive FCF years: 3
· Gross Profitability (Novy-Marx) — Gross profit / assets: 47.3% · Gross margin: 86.6%
· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.60 · Operating cash flow: $2.2B · Net income: $1.3B
· Bought by Members — Members buying: 2 · Buy txns: 4 · Sell txns: 2 · Latest buy: Jun 5, 2026
· Bought by Both Parties — Members buying: 2 · Buy txns: 4 · Sell txns: 2 · Latest buy: Jun 5, 2026
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Politician BEST — appeared in 1 of the last 20 quarterly lists; latest 2026 Q2, ranked #11 of 50.
| 13F signal (2021 Q3 – 2026 Q1) | Events | Win rate | Avg return | SPY | Excess |
|---|---|---|---|---|---|
| Heavy accumulation — 3+ tracked funds increased together | 5 | 60.0% | +11.4% | +3.5% | +7.9% |
Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.
Also held by the tracked funds that hold BIIB: UNITEDHEALTH GROUP INC (UNH) · Ascendis Pharma A/S (ASND) · PFIZER INC (PFE) · BOSTON SCIENTIFIC CORP (BSX) · MICROSOFT CORP (MSFT) · Alphabet Inc. (GOOGL) · Meta Platforms, Inc. (META) · TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD (TSM) · Alphabet Inc. (GOOG) · NVIDIA CORP (NVDA).
Filings audit: every filing lens on BIOGEN INC. (BIIB), scored — GetCoattail Research.
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.